SCHEMBL3921706

SCHEMBL3921706

COC(=O)c1ccc(CS(=O)(=O)c2ccncc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
LOXL2 Q9Y4K0 1/20 0.53
NAMPT P43490 3/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
KMT2A Q03164 1/20 0.47
POLB P06746 3/20 0.46
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CYP4A11 Q02928 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916464 0.85 POLB (0.62) MAPTCYP3A4CYP2C9LOXL2CA12
SCHEMBL23329736 0.82 LMNA (0.61) MAPTCYP3A4CYP2C9LOXL2CA12
SCHEMBL19398871 0.82 CYP3A4 (0.60) MAPTCYP3A4CYP2C9LOXL2CA12
SCHEMBL7165531 0.82 POLB (0.65) MAPTCYP3A4CYP2C9LOXL2CA12
SCHEMBL1020486 0.81 ALDH1A1 (0.54) MAPTCYP3A4CYP2C9NAMPTCA2
SCHEMBL19398872 0.80 ALDH1A1 (0.64) MAPTCYP3A4CYP2C9KMT2APOLB
SCHEMBL4712178 0.79 MAPT (0.58) MAPTCYP3A4CYP2C9LOXL2CA12
SCHEMBL3909036 0.78 HDAC1 (0.62) MAPTLOXL2NAMPTCA12CA1
SCHEMBL7978843 0.78 CYP4A11 (0.62) MAPTCYP3A4CYP2C9LOXL2NAMPT
SCHEMBL27556687 0.77 LOXL2 (0.61) MAPTLOXL2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495022-B2 α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors SK CHEMICALS CO., LTD. (KR) 2009-02-24 US disclosed
US-20050124679-A1 Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors SK CHEMICALS CO., LTD. (KR) 2005-06-09 US disclosed
WO-2003087066-A1 α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS SK CHEMICALS, CO., LTD. (KR) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124679-A1 Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors HDAC1, HDAC5, HDAC9 MAPT 4083/4885CYP3A4 4556/4885CYP2C9 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.